Sebastian Böttcher

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 16

Top Venues

Blood advances

Blood

Cancers

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Stephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, Matthew S Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T Ghanim, Michael Moran, Wendy J Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G Wierda, John Francis Seymour
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood advances 8 (8) (2024)
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial. Blood 144 (3) (2024)
Stephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, Matthew S Davids, Barbara Eichhorst, Michael J Hallek, Peter Hilmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T Ghanim, Michael Moran, Wendy J Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G Wierda, John Francis Seymour
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood advances (2024)
Stephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, Matthew S Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T Ghanim, Michael Moran, Wendy J Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G Wierda, John Francis Seymour
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood advances 8 (8) (2024)
Stephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, Matthew S Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T Ghanim, Michael Moran, Wendy J Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G Wierda, John Francis Seymour
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood advances 8 (8) (2024)
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial. Blood (2024)
Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Fürstenau, Valentin Goede, Julia von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens M Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner J Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P Kater, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Othman Al-Sawaf
Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Robby Engelmann, Nadja Jäkel, Sabrina Jotschke, Beatrice Ludwig-Kraus, Frank Bernhard Kraus, Neha Kumari, Susann Schulze, Michael Hecker, Christina Zahn, Haifa Kathrin Al-Ali, Christian Junghanss, Sebastian Böttcher
Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia. Blood advances (2023)
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Othman Al-Sawaf, Karl-Anton Kreuzer, Anna Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Final analysis of the CLL2-GIVe trial (obinutuzumab, ibrutinib, and venetoclax) in untreated CLL with del(17p)/TP53mut. Blood (2023)
Julia von Tresckow, Paula Cramer, Sandra Robrecht, Petra Langerbeins, Anna-Maria Fink, Othman Al-Sawaf, Moritz Fürstenau, Thomas Illmer, Holger Klaproth, Eugen Tausch, Matthias Ritgen, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara F Eichhorst, Michael Hallek
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia 36 (8) (2022)
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna L Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood 139 (9) (2022)
Sabrina Jotschke, Susann Schulze, Nadja Jäkel, Beatrice Ludwig-Kraus, Robby Engelmann, Frank Bernhard Kraus, Christina Zahn, Nicole Nedlitz, Gabriele Prange-Krex, Johannes Mohm, Bettina Peuser, Maik Schwarz, Claudia Spohn, Timo Behlendorf, Mascha Binder, Christian Junghanss, Sebastian Böttcher, Haifa Kathrin Al-Ali
Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). Cancers 14 (6) (2022)
Łukasz Sędek, Juan A Flores-Montero, Alita van der Sluijs, Jan Kulis, Jeroen Te Marvelde, Jan Philippé, Sebastian Böttcher, Marieke Bitter, Joana Caetano, Vincent H J van der Velden, Edwin Sonneveld, Chiara Buracchi, Ana Helena Santos, Margarida Lima, Shaji K Kumar, Jacques J M van Dongen, Alberto Orfao
Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels. Cancers 14 (3) (2022)
Anke Schilhabel, Peter Jonas Walter, Paula Cramer, Julia von Tresckow, Saskia Kohlscheen, Monika Szczepanowski, Anna Laqua, Kirsten Fischer, Barbara Eichhorst, Sebastian Böttcher, Christof Schneider, Eugen Tausch, Monika Brüggemann, Michael Kneba, Michael Hallek, Matthias Ritgen
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. Cancers 14 (19) (2022)
Sebastian Böttcher, Robby Engelmann, Georgiana Grigore, Paula Carolina Fernandez, Joana Caetano, Juan A Flores-Montero, Vincent H J van der Velden, Michaela Novakova, Jan Philippé, Matthias Ritgen, Leire Burgos, Quentin Al Lecrevisse, Sandra Lange, Tomáš Kalina, Javier Verde, Rafael Fluxa, Jacques J M van Dongen, Carlos E Pedreira, Alberto Orfao
Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. Blood advances (2021)
Othman Al-Sawaf, Can Zhang, Tong Lu, Michael Z Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, Maneesh Tandon, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Sebastian Böttcher, Karl-Anton Kreuzer, Brenda Chyla, Dale Miles, Clemens-Martin Wendtner, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Sebastian Böttcher.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sebastian Böttcher